Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01333111 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 74
- Enrollment target
NCT01333111 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 74 participants.
The verdict
NCT01333111, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 74 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, Japan and North America. The aim of this trial is to evaluate the safety and efficacy, including pharmacokinetics (the rate at which the body eliminates the trial drug), of NNC-0156-0000-0009 (nonacog beta pegol) when used for treatment and prophylaxis of bleeding episodes in patients with haemophilia B.
Interventions
- DRUG nonacog beta pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2011-04-27 |
| Est. Completion | 2013-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01333111
The ClinicalTrials.gov registry entry for NCT01333111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nonacog beta pegol is the first listed.
NCT01333111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01333111 about?
NCT01333111 is a clinical study titled "Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients". This trial is conducted in Africa, Asia, Europe, Japan and North America. The aim of this trial is to evaluate the safety and efficacy, including pharmacokinetics (the rate at which the body eliminates the trial drug), of NNC-0156-0000-0009 (nonacog beta pegol) when used for treatment and prophylaxi...
What is the current status of trial NCT01333111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2011-04-27. Estimated completion is 2013-03-31.
What interventions are being tested in trial NCT01333111?
The interventions under investigation include: nonacog beta pegol (DRUG).
Who is sponsoring clinical trial NCT01333111?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.